An interventional study of Prednisone and Placebo in Heart Transplant Rejection, sponsored by CareDx. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by CareDx · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
MERIT is a double-blind, multi-center, placebo-controlled, randomized clinical trial. Heart transplant recipients with dual-positive GEP/dd-cfDNA assays with a corresponding negative biopsy between 2 months and 2 years post-transplant will be randomized to treatment with either high-dose oral steroids or placebo, in addition to standard of care therapy.
This study is a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial enrolling approximately 200 adult heart transplant recipients across up to 20 transplant centers in the United States and Canada. Eligible participants are adults (≥18 years) between 2 months and 2 years post-heart transplant who have simultaneous dual-positive molecular testing-defined as both an elevated gene expression profiling (GEP) and elevated donor derived cell-free DNA (dd-cfDNA) result-paired with an endomyocardial biopsy showing no evidence of acute rejection (ISHLT grade 0R or 1R and pAMR0).
Participants will be randomized in a 1:1 ratio to receive either high-dose oral prednisone (100 mg daily for 3 consecutive days) or matched placebo, in addition to standard of care therapy. Treatment assignment will be blinded to participants, investigators, and study personnel.
The primary objective is to determine whether high-dose steroid therapy improves clinical outcomes at 180 days following randomization.
Participants will be followed for 12 months after randomization, with scheduled assessments at 28 days, 180 days, and 365 days, including clinical evaluation, laboratory testing, echocardiography, and molecular biomarker measurements.
By evaluating whether early intervention based on molecular evidence of graft injury can improve outcomes, this study aims to inform clinical decision-making and potentially establish a new treatment paradigm for heart transplant recipients with molecular evidence of allograft injury that is not detected by biopsy.
CareDx is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Simultaneous dual-positive GEP/dd-cfDNA result, defined as both a dd-cfDNA level ≥0.20% AND one of the following:
An endomyocardial (EMB) showing no rejection [(0R or 1R) and pAMR0] AND both of the following:
If the closest GEP/dd-cfDNA result prior to screening was also dual positive, both of the following must be true:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three days, 100mg of prednisone
Drug: Prednisone
Matched placebo
Drug: Placebo
100mg per day for three days following randomization
Matched placebo in same patient population.
Primary Endpoint
A hierarchical composite outcome of time to death or re-transplantation, time to graft dysfunction (LVEF \<50%), time to ACR 2R higher and/or pAMR1 or higher, hospitalization (yes/no), dd-cfDNA \<0.20% (yes/no), and percent reduction in dd-cfDNA from randomization.
Time frame: Assessed at 180 (± 14) days post-randomization
Secondary Endpoint
A hierarchical composite outcome of time to death or re-transplantation, time to graft dysfunction (LVEF \<50%), time to ACR 2R higher and/or pAMR1 or higher, hospitalization (yes/no), dd-cfDNA \<0.20% (yes/no), and percent reduction in dd-cfDNA from randomization.
Time frame: Assessed at 28 (±7) days post-randomization
Safety Endpoint
Incidence of infection requiring treatment with antibiotics, antivirals, and/or antifungals, hyperglycemia requiring an unplanned clinic visit, emergency room visit or hospitalization, and bone fracture or avascular necrosis.
Time frame: Randomization through study completion, an average of 1 year.
6 Month Exploratory Endpoint
Evaluate additional biomarkers including DSA and Teno torque virus (TTV) levels; presence of ≥1 de novo DSA.
Time frame: Assessed at 180 (± 14) days post-randomization
12 Month Exploratory Endpoint
A hierarchical composite outcome of time to death or re-transplantation, time to graft dysfunction (LVEF \<50%), time to ACR 2R higher and/or pAMR1 or higher, hospitalization (yes/no), dd-cfDNA \<0.20% (yes/no), and percent reduction in dd-cfDNA from randomization.
Time frame: Assessed at 365 (±30) days post-randomization
No study locations are listed for this record.
Start is estimated for Mar 2027; primary completion for Dec 2028, 21 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prednisone
CareDx